Quarterly ResultAug 5, 2026, 07:33 AM
Immuneering Q2 Net Loss $17.3M; Atebimetinib Phase 3 Underway, Positive ASCO Data
AI Summary
Immuneering Corporation reported a Q2 2026 net loss of $17.3 million, or $0.27 per share, and ended the quarter with $182.7 million in cash, cash equivalents, and marketable securities, providing an anticipated cash runway into 2029. The company announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line pancreatic cancer is underway, with positive Phase 2a data showing a 17.3-month median overall survival and favorable tolerability presented at ASCO. Additionally, Immuneering appointed Andrew Gengos as CFO and published preclinical findings for atebimetinib in Cancer Research.
Key Highlights
- Q2 2026 Net Loss: $17.3 million, or $0.27 per share.
- Cash, cash equivalents, and marketable securities: $182.7 million as of June 30, 2026.
- Anticipated cash runway: into 2029.
- Atebimetinib Phase 2a data: 17.3 month median overall survival in 55 pancreatic cancer patients.
- Phase 3 MAPKeeper 301 trial: underway with patients being dosed.
- Q2 2026 R&D expenses: $14.0 million, up from $10.5 million in Q2 2025.
- Andrew Gengos appointed as Chief Financial Officer in June.
- Atebimetinib preclinical data published in Cancer Research.
Price Impact
More from IMRX